Metraipolis › archive › dc_42bb27e2ef16
5 Alpha Reductase Inhibitors (5ARIs) Monotherapy and Combinations: Current Role in Benign Prostatic Hyperplasia (BPH) Management — Europe PMC PMID:42195228
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42195228
- DOI
- 10.3390/medicina62050975
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-02T05:43:19.382Z
- SHA-256 of the archived text
c7509c5f3ffcb8aad2651f68096fc4776712e34e7772f8fa89bbc8ee05bab002- Stable URL of this page
https://metraipolis.com/documento/dc_42bb27e2ef16
How to cite
5 Alpha Reductase Inhibitors (5ARIs) Monotherapy and Combinations: Current Role in Benign Prostatic Hyperplasia (BPH) Management — Europe PMC PMID:42195228 — Europe PMC (en), https://europepmc.org/article/MED/42195228 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_42bb27e2ef16 (Metraipolis archive dc_42bb27e2ef16, sha256 c7509c5f3ffcb8aad2651f68096fc4776712e34e7772f8fa89bbc8ee05bab002)
BibTeX
@misc{dc42bb27e2ef16,
title = {5 Alpha Reductase Inhibitors (5ARIs) Monotherapy and Combinations: Current Role in Benign Prostatic Hyperplasia (BPH) Management — Europe PMC PMID:42195228},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42195228},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_42bb27e2ef16; sha256 c7509c5f3ffcb8aad2651f68096fc4776712e34e7772f8fa89bbc8ee05bab002},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42195228. Agents can read the archived copy with the MCP tool read_document.